Cellino successfully manufactures and delivers autologous iPSC lines from four donors to Matricelf for groundbreaking neural tissue engineering.

Matricelf transformed Cellino-generated iPSCs into functional neural tissues with synchronized electrical activity.

CAMBRIDGE, Mass. –  Cellino and Matricelf (TASE: MTLF) announced a collaboration to accelerate the global biomanufacturing of personalized spinal cord injury treatments using Cellino’s Nebula™ technology combined with Matricelf’s breakthrough regenerative approach. This collaboration combines Cellino’s automated iPSC manufacturing with Matricelf’s double autologous 3D differentiation process, paving the way for scalable, patient-specific regenerative therapies. [Read more…]

MONT-SAINT-GUIBERT, Belgium — Cellistic, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, announces the launch of its Allo Chassis™—ready-to-use, immune-cloaked iPSC cell lines derived from CD34+ and CD4+ T-cell primary cells. These innovative cell lines represent a substantial leap forward in cell line development, effectively reducing both timelines and costs. Leveraging Cellistic’s extensive expertise in iPSCs, including in the development of T-cell based treatments, the Allo Chassis™ cell lines set a new standard in the cell therapy market with their unprecedented technology, developed in accordance with current Good Manufacturing Practice (cGMP) standards. [Read more…]